In early 1983, Bolar Pharmaceutical Inc. wanted to bring a generic version of the Dalmane drug, a sleeping pill, to the market. At that time, Roche Products Inc. held patent rights for flurazepam hydrochloride, the active ingredient in the drug. Considering that the success of a generic drug highly depends on the time it is brought to market, Bolar started working on the medication before the patent expired, aiming to have the drug ready to sell as soon as...
↧